SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-001535
Filing Date
2021-08-23
Accepted
2021-08-23 08:05:20
Documents
14
Period of Report
2021-08-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20210819.htm   iXBRL 8-K 51707
2 EX-10.1 virx-20210819ex10_1.htm EX-10.1 31458
3 EX-99.1 virx-20210819ex99_1.htm EX-99.1 22276
  Complete submission text file 0000950170-21-001535.txt   231732

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20210819_pre.xml EX-101.PRE 9581
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20210819_lab.xml EX-101.LAB 12936
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20210819.xsd EX-101.SCH 2426
7 EXTRACTED XBRL INSTANCE DOCUMENT virx-20210819_htm.xml XML 4549
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 211195404
SIC: 2834 Pharmaceutical Preparations